Drugs & Targets FDA gives accelerated approval for Blincyto for ALL patients with minimal residual disease March 30, 2018Vol.44 No.13
Drugs & Targets Enfortumab vedotin gets breakthrough designation in urothelial cancer March 30, 2018Vol.44 No.13
Drugs & Targets FDA approves changes on Hologic’s 3Dimensions Mammography System March 30, 2018Vol.44 No.13
Drugs & Targets FDA accepts application for Opdivo plus Yervoy for MSI-H or dMMR metastatic colorectal cancer for priority review March 30, 2018Vol.44 No.13
Drugs & Targets Novartis’s Tasigna approved for children with rare form of leukemia March 23, 2018Vol.44 No.12
Drugs & Targets FDA approves Adcetris for adults with previously untreated stage III or IV classical Hodgkin lymphoma March 23, 2018Vol.44 No.12
Drugs & Targets University of Maryland certified for CAR T-cell therapy in lymphoma March 23, 2018Vol.44 No.12
Drugs & Targets Erdafitinib gets Breakthrough Therapy designation for metastatic urothelial cancer March 16, 2018Vol.44 No.11
Drugs & Targets FDA grants priority review to Merck’s sBLA for Keytruda for advanced cervical cancer March 16, 2018Vol.44 No.11
Drugs & TargetsFree Lilly receives additional FDA approval for Verzenio for advanced breast cancer March 02, 2018Vol.44 No.09
